PRTA

6.70

0.89% -0.06

시장 영업 전: 6.71 0.010 +0.15%

Prothena Corporation Plc (PRTA)

개요 뉴스 가격 이력 옵션 체인 Financials PRTA 왜 하락? 토론 예측

전일 마감가:

$6.76

열려 있는:

$6.72

하루 거래량:

717.76K

Relative Volume:

0.42

시가총액:

$360.64M

수익:

$217.25M

순이익/손실:

$-50.92M

주가수익비율:

-6.70

EPS:

-1

순현금흐름:

$-100.85M

1주 성능:

+3.55%

1개월 성능:

+10.38%

6개월 성능:

-57.11%

1년 성능:

-72.05%

1일 변동 폭

$6.54

$6.758

1주일 범위

$6.24

$6.84

52주 변동 폭

$4.32

$25.42

Prothena Corporation Plc Stock (PRTA) Company Profile

명칭

Prothena Corporation Plc

부문

Healthcare (1161)

산업

Biotechnology (651)

전화

011-353-1-236-2500

주소

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2

직원

163

트위터

@ProthenaCorp

다음 수익 날짜

2025-02-18

최신 SEC 제출 서류

PRTA's Discussions on Twitter

PRTA을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
PRTA Prothena Corporation Plc	6.70	363.87M	217.25M	-50.92M	-100.85M	-1.00
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-05-28	다운그레이드	BofA Securities	Neutral → Underperform
2025-05-27	다운그레이드	Cantor Fitzgerald	Overweight → Neutral
2025-05-27	다운그레이드	Jefferies	Buy → Hold
2025-05-27	다운그레이드	Oppenheimer	Outperform → Perform
2024-12-20	개시	Chardan Capital Markets	Buy
2024-01-30	다운그레이드	BofA Securities	Buy → Neutral
2023-12-12	개시	Deutsche Bank	Buy
2023-04-24	개시	SVB Securities	Outperform
2023-01-27	개시	Piper Sandler	Overweight
2022-11-04	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-09-28	업그레이드	BofA Securities	Neutral → Buy
2021-11-19	개시	JMP Securities	Mkt Outperform
2021-06-18	업그레이드	BofA Securities	Underperform → Neutral
2021-06-08	재확인	Oppenheimer	Outperform
2021-05-26	개시	Citigroup	Buy
2021-02-26	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2021-02-12	업그레이드	Jefferies	Hold → Buy
2021-02-02	업그레이드	BTIG Research	Neutral → Buy
2020-12-07	개시	H.C. Wainwright	Buy
2020-07-09	업그레이드	Oppenheimer	Perform → Outperform
2019-11-19	업그레이드	Evercore ISI	In-line → Outperform
2018-05-21	다운그레이드	Barclays	Equal Weight → Underweight
2018-04-23	다운그레이드	Jefferies	Buy → Hold
2018-04-05	재확인	Barclays	Overweight
2017-11-20	다운그레이드	Wedbush	Outperform → Neutral
2017-09-29	재확인	BTIG Research	Buy
2017-09-15	개시	RBC Capital Mkts	Outperform
2017-08-17	개시	Evercore ISI	Outperform
2017-07-11	개시	Jefferies	Buy
2017-04-12	개시	Cantor Fitzgerald	Overweight
2017-04-12	개시	Piper Jaffray	Overweight
2017-03-02	개시	Instinet	Buy
2016-12-21	개시	SunTrust	Buy
2016-11-03	개시	Deutsche Bank	Buy
2016-08-04	재확인	Barclays	Overweight
2016-05-13	개시	Barclays	Overweight
2016-02-19	재확인	Wedbush	Outperform
2016-01-21	개시	Credit Suisse	Outperform

모두보기

Prothena Corporation Plc 주식(PRTA)의 최신 뉴스

Jul 24, 2025

What analysts say about Prothena Corporation plc stockFree AI-Backed Trading Signals - Autocar Professional

Jul 24, 2025

What drives Prothena Corporation plc stock priceFree Stock Market Real-Time Monitoring - PrintWeekIndia

Jul 24, 2025

Jul 23, 2025

Is Prothena Corporation plc a good long term investmentHigh-velocity gains - jammulinksnews.com

Jul 23, 2025

Prothena Corporation plc (NASDAQ:PRTA) Receives $31.50 Average Price Target from Analysts - Defense World

Jul 23, 2025

Prothena Corporation plc Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com

Jul 23, 2025

Jul 17, 2025

How to Take Advantage of moves in (PRTA) - news.stocktradersdaily.com

Jul 17, 2025

Jul 15, 2025

Why Prothena Corporation plc stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser

Jul 15, 2025

What makes Prothena Corporation plc stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 15, 2025

How Prothena Corporation plc stock performs during market volatilityFree Capital Allocation Plans - Newser

Jul 15, 2025

Cambridge Investment Research Advisors Inc. Acquires Shares of 10,164 Prothena Corporation plc (NASDAQ:PRTA) - Defense World

Jul 15, 2025

Jul 14, 2025

Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN

Jul 14, 2025

Jul 04, 2025

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? - sharewise.com

Jul 04, 2025

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - MSN

Jul 04, 2025

Jun 20, 2025

Prothena to lay off majority of staff; Zealand shares obesity drug data - BioPharma Dive

Jun 20, 2025

Jun 19, 2025

Peninsula biotech will cut half its workforce, but partner takes Parkinson's drug into late-stage trial - The Business Journals

Jun 19, 2025

Jun 18, 2025

Prothena announces 63% workforce reduction following birtamimab halt - Investing.com

Jun 18, 2025

Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus

Jun 18, 2025

Prothena to cut workforce by 63% amid strategic review - Investing.com

Jun 18, 2025

Prothena announces corporate restructuring - MarketScreener

Jun 18, 2025

Prothena Announces Corporate Restructuring - Business Wire

Jun 18, 2025

Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN

Jun 18, 2025

Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World

Jun 18, 2025

Jun 17, 2025

Roche And Prothena: Why Moving On Makes Sense (OTCMKTS:RHHBY) - Seeking Alpha

Jun 17, 2025

Jun 16, 2025

(PRTA) Trading Signals - news.stocktradersdaily.com

Jun 16, 2025

Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX

Jun 16, 2025

Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha

Jun 16, 2025

Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks

Jun 16, 2025

Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria

Jun 16, 2025

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace

Jun 16, 2025

Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com

Jun 16, 2025

Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus

Jun 16, 2025